AMG-208 is primarily investigated for its potential therapeutic applications in cancer treatment. It functions as a selective inhibitor of the c-Met receptor tyrosine kinase, which plays a critical role in tumor growth, metastasis, and angiogenesis. By targeting this pathway, AMG-208 aims to disrupt the signaling mechanisms that promote cancer cell survival and proliferation. It has been studied in preclinical and clinical settings for its efficacy in treating various cancers, particularly those with c-Met dysregulation, such as certain types of lung, gastric, and renal cancers. Its application is focused on improving outcomes for patients with advanced or treatment-resistant malignancies.